Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) EBT Margin (2017 - 2025)

Historic EBT Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 1.97%.

  • Akebia Therapeutics' EBT Margin rose 555100.0% to 1.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.79%, marking a year-over-year decrease of 3187300.0%. This contributed to the annual value of 43.33% for FY2024, which is 4759200.0% up from last year.
  • Latest data reveals that Akebia Therapeutics reported EBT Margin of 1.97% as of Q3 2025, which was up 555100.0% from 0.4% recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' EBT Margin peaked at 22.98% during Q2 2022, and registered a low of 159.32% during Q2 2021.
  • For the 5-year period, Akebia Therapeutics' EBT Margin averaged around 56.86%, with its median value being 49.04% (2024).
  • Data for Akebia Therapeutics' EBT Margin shows a peak YoY increase of 2767200bps (in 2021) and a maximum YoY decrease of -646800bps (in 2021) over the last 5 years.
  • Over the past 5 years, Akebia Therapeutics' EBT Margin (Quarter) stood at 122.1% in 2021, then surged by 90bps to 11.66% in 2022, then soared by 96bps to 0.48% in 2023, then tumbled by -10158bps to 49.04% in 2024, then soared by 104bps to 1.97% in 2025.
  • Its EBT Margin was 1.97% in Q3 2025, compared to 0.4% in Q2 2025 and 10.66% in Q1 2025.